1-formyloxy-2-tert-butoxy ethane | 129345-71-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-formyloxy-2-tert-butoxy ethane
• 英文别名: 2-[(2-Methylpropan-2-yl)oxy]ethyl formate
• CAS: 129345-71-7
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: KXVOLASCEFTIIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  170.3±23.0 °C(Predicted)
• 密度：
  0.9306 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-乙氧基-1,3-二氧戊环 、 叔丁氧基三甲基硅烷 以20%的产率得到
  参考文献：
  名称：

  ZHURKINA, I. P.;NEDOGREJ, E. P.;MUSAVIROV, R. S.;KONDRATEVA, I. A.;RAXMAN+, ZH. PRIKL. XIMII, 63,(1990) N, S. 370-375

  摘要：

  DOI：

文献信息

• PHENYLIMIDAZOLE DERIVATIVE, AND THERAPEUTIC MEDICINE OR PREVENTIVE MEDICINE FOR INFLAMMATORY DISEASE, ETC.
  申请人：NIPPON SODA CO., LTD.

  公开号：US20160145242A1

  公开（公告）日：2016-05-26

  A medicinal active ingredient is provided which is useful for the treatment or prevention of inflammatory diseases, diseases caused by lipid oxidation, retinochoroidal disorders. A phenylimidazole derivative represented by Formula (IB) or a salt thereof is provided. A therapeutic medicine or preventive medicine is provided for inflammatory diseases, diseases caused by lipid oxidation, or retinochoroidal disorders, the medicine including at least one selected from the phenylimidazole derivative, a salt thereof, and metabolites thereof as an active ingredient. In Formula (IB), R 1a represents an alkyl group etc., R 2 represents an amino group etc., R 3 represents a halogen atom, an alkyl group etc., R 4 represents a cyano group etc., R 5 represents an alkyl group etc., and R 6 represents an alkyl group etc.

  提供了一种药用活性成分，可用于治疗或预防炎症性疾病、脂质氧化引起的疾病、视网膜脉络膜疾病。提供了一种由式（IB）所代表的苯基咪唑衍生物或其盐，该衍生物可用作治疗或预防炎症性疾病、脂质氧化引起的疾病或视网膜脉络膜疾病的治疗药物或预防药物，该药物包括至少选自苯基咪唑衍生物、其盐和其代谢物中的一种作为活性成分。在式（IB）中，R1代表烷基等，R2代表氨基等，R3代表卤素原子、烷基等，R4代表氰基等，R5代表烷基等，R6代表烷基等。
• [EN] PRODRUG ESTERS OF CEFTRIAXONE<br/>[FR] ESTERS DE PROMEDICAMENT DE CEFTRIAXONE
  申请人：RANBAXY LAB LTD

  公开号：WO2004046153A1

  公开（公告）日：2004-06-03

  The invention relates to prodrug esters of ceftriaxone. The invention also relates to processes for preparing prodrug esters of ceftriaxone, pharmaceutical compositions that include the prodrug esters and to methods for using the prodrug esters. The prodrug esters of ceftriaxone are useful as antimicrobial agents and are suitable for oral administration.

  该发明涉及头孢曲松的前药酯类。该发明还涉及制备头孢曲松前药酯类的过程、包括前药酯类的制药组合物以及使用前药酯类的方法。头孢曲松的前药酯类可用作抗微生物剂，并适合口服给药。
• Cephalosporin compound, method of its production and composition for prevention and treatment of bacterial infectious diseases
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：EP0300423A2

  公开（公告）日：1989-01-25

  A cephalosporin compound represented by the formula (I): wherein R' represents a hydrogen atom or a-amino acid residue (ester bonding), its ester, or its pharmacologically acceptable salt, which is useful as a preventive, therapeutic drug for bacterial infections as well as an intermediate for the synthesis of other cephalosporin compounds, a method of its production, a pharmaceutical composition for prevention and treatment of bacterial infectious diseases and method for the treatment of bacterial infectious diseases.

  一种由式（I）代表的头孢菌素化合物： 其中 R'代表氢原子或 a-氨基酸残基（酯键）、其酯或其药理学上可接受的盐，可用作细菌感染的预防和治疗药物，以及合成其他头孢菌素化合物的中间体、其生产方法、预防和治疗细菌感染性疾病的药物组合物和治疗细菌感染性疾病的方法。
• N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF
  申请人：UBE INDUSTRIES LIMITED

  公开号：EP1020467A1

  公开（公告）日：2000-07-19

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了式 (I) 所代表的化合物： 其中 A 代表下式（a-1）或下式（a-2）： B 代表下式（b）： (其中各符号如说明书中所定义）或其药学上可接受的盐类，以及用于制备它们的中间体，它们具有优异的血小板聚集抑制活性和其他特性，可用作与纤维蛋白原受体、血栓形成、梗塞等相关疾病的预防或治疗药物。
• RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME
  申请人：Japan as represented by Secretary of Agency of Industrial Science and Technology

  公开号：EP1114836A1

  公开（公告）日：2001-07-11

  A curable resin composition, which comprises a resin formed, in the presence of a transition metal complex, by polymerizing an oxidative-polymerizable compound that contains a phenol-compound-containing vegetable oil. A method for producing a curable resin composition comprising a resin formed, in the presence of a catalyst, by polymerizing an oxidative-polymerizable compound that contains a phenol-compound-containing vegetable oil, wherein the catalyst is a transition metal complex. The curable resin composition is useful as a raw material for a urushi-like coating, a friction material, a brake lining material, a brake pad material, a material for forming a coating film, a compound for a recording material, a raw material for an ink, a raw material for a coating, a raw material for a adhesive, a raw material for an epoxy resin, a raw material for a photoresist or antioxidant, and a starting material for a functional polymer.

  一种可固化树脂组合物，它包括在过渡金属络合物存在下，通过聚合含有含酚化合物的植物油的可氧化聚合化合物而形成的树脂。一种生产可固化树脂组合物的方法，该树脂组合物包括在催化剂存在下，通过聚合含有含酚化合物植物油的可氧化聚合化合物而形成的树脂，其中催化剂为过渡金属络合物。这种可固化树脂组合物可用作乌拉石般的涂层的原料、摩擦材料、制动衬片材料、制动片材料、形成涂膜的材料、记录材料的化合物、油墨的原料、涂层的原料、粘合剂的原料、环氧树脂的原料、光刻胶或抗氧化剂的原料以及功能聚合物的起始原料。